AstraZeneca

In News

AstraZeneca, after phase 3 miss, posts subgroup data behind pitch for rare disease approval - Fierce Biotech

Fierce Biotech - May 29, 2026

ASCO26: AstraZeneca’s light chain amyloidosis shows subgroup benefit after Phase III trial - Yahoo

Yahoo - May 29, 2026

AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions - Endpoints News

Endpoints News - May 29, 2026

AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi - Fierce Pharma

Fierce Pharma - May 28, 2026

Kailera’s own ‘triple-G’ drug also looks very powerful - statnews.com

statnews.com - May 27, 2026

US regulator delays decision on AstraZeneca cancer drug - Financial Times

Financial Times - May 27, 2026

AstraZeneca’s ‘game changer’ cancer pill stuck in limbo as FDA demands more data - the-independent.com

the-independent.com - May 27, 2026

FDA delays ruling on AstraZeneca drug after negative adcomm vote - Fierce Biotech

Fierce Biotech - May 27, 2026

AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave - Endpoints News

Endpoints News - May 27, 2026

AstraZeneca's blood pressure drug wins U.S. approval - Reuters

Reuters - May 17, 2026

US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data - AstraZeneca

AstraZeneca - May 27, 2026

State grant could help Albemarle attract a neighbor for AstraZeneca - Cville Right Now

Cville Right Now - May 30, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment